Bard buys ultrasound manufacturer Dymax:
This article was originally published in Clinica
CR Bard has bought privately-owned Dymax for an undisclosed sum. The transaction will bring Bard the Site-Right II, a small, battery-operated, portable ultrasound system which is used to guide needles for percutaneous vascular access. The device enables the surgeon to see the vessel, observe the needle puncture and place a line with fewer attempts. Bard will also get Dymax' TM18 ultrasound scanners, probes, needle guides and other accessories. The product line will be sold through Bard's Salt Lake City, Utah-based access systems subsidiary.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.